Ask AI
2025 ASH Lymphomas

CE / CME

Key Studies in Lymphomas/CLL: Independent Conference Coverage of the 2025 ASH Annual Meeting

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: February 26, 2026

Expiration: August 25, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Al-Sawaf O, Stumpf J, Zhang C, et al. Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: results from the randomized CLL17 trial. Presented at the 2025 Annual Meeting of the American Society of Hematology. Abstr 1.
  2. Al-Sawaf O, Stumpf J, Zhang C, et al. Fixed-duration versus continuous treatment for chronic lymphocytic leukemia. N Engl J Med. 2025;[Epub ahead of print].
  3. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: CLL/SLL v1.2026. nccn.org. Accessed February 20, 2026.
  4. Brown JR, Seymour JF, Jurczak W, et al. Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. N Engl J Med. 2025;392:748-762.
  5. Jurczak W, Kwiatek M, Czyz J, et al. Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: first results from a randomized phase III study examining a non-covalent BTK inhibitor in untreated patients. Presented at the 2025 Annual Meeting of the American Society of Hematology. Abstr LBA-3.
  6. Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39:3441-3452.
  7. Brown JR, Eichhorst B, Lamanna N, et al. Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE. Blood. 2024;144:2706-2717.
  8. Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397:892-901.
  9. Sharman JP, Munir T, Grosicki S, et al. Phase III trial of pirtobrutinib versus idelalisib/rituximab or bendamustine/rituximab in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (BRUIN CLL-321). J Clin Oncol. 2025;43:2538-2549.
  10. Pirtobrutinib [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2025.
  11. Ahn IE, Parrondo RD, Thompson MC, et al. Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma from the ongoing phase 1 CaDAnCe-101 study. Presented at the 2025 Annual Meeting of the American Society of Hematology. Abstr 28.
  12. Wang H, Hou X, Zhang W. BGB-16673, a BTK degrader, overcomes on-target resistance from BTK inhibitors and presents sustainable long-term tumor regression in lymphoma xenograft models. Presented at the 2025 European Hematology Association Congress. Abstr P1219.
  13. Feng X, Wang Y, Long T, et al. Bruton tyrosine kinase (BTK) protein degrader BGB-16673 is less apt to cause, and able to overcome variable BTK resistance mutations compared to other BTK inhibitors (BTKi). Presented at the 2025 European Hematology Association Congress. Abstr 1239.
  14. Falchi L, Nijland M, Huang H, et al. Primary phase 3 results from the EPCORE FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma. Presented at the 2025 Annual Meeting of the American Society of Hematology. Abstr 466.
  15. Epcoritamab [prescribing information]. Plainsboro, NJ: Genmab US, Inc.; 2025.
  16. Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37:1188-1199.
  17. Sehn LH, Hübel K, Luminari S, et al. Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial. Lancet. 2026;407:133-146.
  18. Tafasitamab-cxix [prescribing information]. Wilmington, DE: Incyte Corporation; 2025.
  19. Hou JZ, Kim TM, Cho SG, et al. Three-year follow-up of the phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with relapsed/refractory (R/R) follicular lymphoma (FL). Presented at the 2025 Annual Meeting of the American Society of Hematology. Abstr 1005.
  20. Wang M, Song Y, Hermine O, et al. Sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) previously treated with a Bruton tyrosine kinase (BTK) inhibitor: early results from a phase 1/2 study. Presented at the 2025 Annual Meeting of the American Society of Hematology. Abstr 663.
  21. Dreyling M, Doorduijn J, Giné E, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. 2024;403:2293-2306.
  22. Wang M, Salek D, Belada D, et al. Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma. J Clin Oncol. 2025;43:2276-2284.
  23. Wang M, Cohen J, Shah N, et al. Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL): final update from the phase 1/2 BRUIN study. Presented at the 2025 Annual Meeting of the American Society of Hematology. Abstr 665.
  24. Wan H, Weng S, Sheng S, Kuang Z, Wang Q, Hu L. Chimeric antigen receptor T-cell therapy in relapsed or refractory mantle cell lymphoma: a systematic review and meta-analysis. Front Immunol. 2024;15:1435127.
  25. Eyre TA, Walter HS, Iyengar S, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019;104:e68-e71. doi:10.3324/haematol.2018.198812
  26. Kim A, Riedell P, Ryan C, et al. Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated mantle cell lymphoma (MAVO). Presented at the 2025 Annual Meeting of the American Society of Hematology. Abstr 664.
  27. Kumar A, Soumerai J, Abramson JS, et al. Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation. Blood. 2025;145:497-507.
  28. Liu J, Li S, Wang Q, et al. Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy. Blood. 2024;143:1825-1836.